Breaking News Instant updates and real-time market news.

DERM

Dermira

$25.89

-0.55 (-2.08%)

, RHHBY

Roche

$31.87

-0.05 (-0.16%)

07:42
08/08/17
08/08
07:42
08/08/17
07:42

Dermira enters into agreement to license lebrikizumab

Dermira (DERM) announced that it has entered into a licensing agreement with F. Hoffmann-La Roche Ltd and Genentech, a member of the Roche Group (RHHBY). Pursuant to the agreement, Dermira will obtain exclusive, worldwide rights to develop and commercialize lebrikizumab, a monoclonal antibody targeting interleukin 13, or IL-13, for atopic dermatitis and all other indications, except Roche will retain certain rights, including exclusive rights to develop and promote lebrikizumab for interstitial lung diseases, such as idiopathic pulmonary fibrosis. Under the terms of the agreement, Dermira will make an initial payment of $80 million to Roche and payments totaling $55 million in 2018. Dermira will also be obligated to make additional payments upon the achievement of certain milestones, comprising $40 million upon the initiation of Dermira's first Phase 3 clinical study, up to $210 million upon the achievement of regulatory and first commercial sale milestones in certain territories and up to $1.025 billion based on the achievement of certain thresholds for net sales of lebrikizumab for indications other than interstitial lung disease. Upon potential regulatory approval, Dermira will make royalty payments representing percentages of net sales that range from the high single-digits to the high teens. The effectiveness of the agreement is subject to expiration or termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act, as amended.

DERM

Dermira

$25.89

-0.55 (-2.08%)

RHHBY

Roche

$31.87

-0.05 (-0.16%)

  • 30

    Nov

DERM Dermira
$25.89

-0.55 (-2.08%)

06/30/17
06/30/17
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Rite Aid (RAD) reinstated with an Underperform at Evercore ISI. 2. Hill-Rom (HRC) initiated with a Buy at Needham and Neutral at Cantor. 3. Dermira (DERM) initiated with an Outperform at Evercore ISI. 4. Coach (COH) initiated with a Buy at Canaccord. 5. WWE (WWE) initiated with an Equal Weight at Morgan Stanley. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
06/29/17
EVER
06/29/17
INITIATION
Target $48
EVER
Outperform
Dermira initiated with an Outperform at Evercore ISI
Evercore analyst Umer Raffat initiated Dermira with an Outperform rating and a $48 price target.
06/22/17
CANT
06/22/17
INITIATION
CANT
Overweight
Dermira initiated with an Overweight at Cantor
Cantor analyst Louise Chen started coverage of Dermira with a $45 price target and a buy rating. The analyst expects the FDA to approve the company's DRM04 drug for excessive sweating in 2018, and she thinks that the company's Cimzia drug for psoriasis could gain more market share than expected.
03/31/17
03/31/17
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Snap (SNAP) initiated with a Market Perform at Wells Fargo. 2. Amazon.com (AMZN) was initiated with a Buy at Loop Capital while Alphabet (GOOG, GOOGL) was initiated with a Hold. 3. Dermira (DERM) initiated with a Buy at Mizuho. 4. TSYS (TSS) initiated with a Buy at Guggenheim. 5. HealthEquity (HQY) initiated with an Overweight at Cantor. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
RHHBY Roche
$31.87

-0.05 (-0.16%)

08/08/17
JEFF
08/08/17
NO CHANGE
Target $75
JEFF
Buy
FibroGen price target raised to $75 from $50 at Jefferies
Jefferies analyst Michael Yee raised his price target for FibroGen (FGEN) shares to $75 saying "significant value creation should occur now" after the company reported positive Phase II idiopathic pulmonary fibrosis lung data for FG-3019. The analyst believes the $5B market capitalization implied by his new price target could prove conservative. InterMune had comparable data and was acquired by Roche (RHHBY) for $8B, Yee tells investors in a research note. The analyst reiterates a Buy rating on FibroGen. The stock in premarket trading is up 59%, or $19.60, to $53.00.
07/14/17
CANT
07/14/17
NO CHANGE
CANT
Worries about Shire hemophilia franchise overdone, says Cantor
After speaking with a pediatric hematology/oncology physician, Cantor analyst Louise Chen reports that the doctor said that uptake of Roche's (RHHBY) hemophilia treatment, ACE910, "will be gradual" because of safety concerns. The analyst says that worries about Shire's (SHPG_) hemophilia franchise are overdone. She keeps a $222 price target and an Overweight rating on the stock.
07/11/17
COWN
07/11/17
NO CHANGE
Target $325
COWN
Outperform
Shire hemophilia franchise being valued near zero, says Cowen
Cowen analyst Ken Cacciatore believes Shire's (SHPG) current valuation reflects essentially no value for the company's hemophilia franchise. Investors are treating Shire/Baxalta's hemophilia franchise as if it should equate to essentially zero, into perpetuity, beginning in 2020, Cacciatore tells investors in a research note, citing his analysis. He believes this sentiment, based on competitive concerns from Roche (RHHBY) and Alnylam (ALNY), is a "gross overreaction." The analyst has an Outperform rating on Shire with a $325 price target.
07/11/17
FBCO
07/11/17
NO CHANGE
Target $96
FBCO
Outperform
Alnylam weakness more driven by competitor data, says Credit Suisse
While attending the ISTH meeting in Berlin, Credit Suisse analyst Alethia Young notes that Alnylam's (ALNY) stock weakness is more driven by "strong" competitor data in inhibitors from Roche's (RHHBY) ACE910. The analyst reiterates an Outperform rating and $96 price target on Alnylam's shares.

TODAY'S FREE FLY STORIES

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

14:17
06/19/18
06/19
14:17
06/19/18
14:17
Technical Analysis
NASDAQ market internals summary »

Volume is above average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WHR

Whirlpool

$146.84

-3.69 (-2.45%)

14:16
06/19/18
06/19
14:16
06/19/18
14:16
Hot Stocks
Whirlpool drops further after AHAM data released »

Shares of Whirlpool have…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

$0.00

(0.00%)

14:16
06/19/18
06/19
14:16
06/19/18
14:16
Technical Analysis
NYSE market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CYDY

CytoDyn

$0.00

(0.00%)

14:15
06/19/18
06/19
14:15
06/19/18
14:15
Conference/Events
CytoDyn participates in lunch meeting with Philadelphia Securities Association »

Luncheon Meeting to be…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Jun

ZS

Zscaler

$37.56

-2.8 (-6.94%)

14:15
06/19/18
06/19
14:15
06/19/18
14:15
Options
Zscaler Inc put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Jul

  • 11

    Jul

YPF

YPF

$16.57

0.35 (2.16%)

14:05
06/19/18
06/19
14:05
06/19/18
14:05
Options
YPF call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

XLNX

Xilinx

$67.79

-1.96 (-2.81%)

13:55
06/19/18
06/19
13:55
06/19/18
13:55
Options
Xilinx put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BAC

Bank of America

$29.19

-0.215 (-0.73%)

13:49
06/19/18
06/19
13:49
06/19/18
13:49
Hot Stocks
Merrill Lynch to pay $42M penalty to settle SEC charges on trade 'masking' »

The Securities and…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FB

Facebook

$195.54

-2.76 (-1.39%)

13:47
06/19/18
06/19
13:47
06/19/18
13:47
Hot Stocks
Facebook takes steps to make video more interactive »

Facebook shares updates…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Jun

COTV

Cotiviti Holdings

$44.00

4.105 (10.29%)

13:43
06/19/18
06/19
13:43
06/19/18
13:43
Downgrade
Cotiviti Holdings rating change  »

Cotiviti Holdings…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SRPT

Sarepta

$140.20

34.72 (32.92%)

13:41
06/19/18
06/19
13:41
06/19/18
13:41
Recommendations
Sarepta analyst commentary  »

Sarepta price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Jun

COTV

Cotiviti Holdings

$44.03

4.14 (10.38%)

13:41
06/19/18
06/19
13:41
06/19/18
13:41
Downgrade
Cotiviti Holdings rating change  »

Cotiviti Holdings…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

13:40
06/19/18
06/19
13:40
06/19/18
13:40
Options
Alerian MLP attracts a large put buyer »

Alerian MLP attracts a…

FMBH

First Mid-Illinois Bancshares

$41.10

0.25 (0.61%)

13:39
06/19/18
06/19
13:39
06/19/18
13:39
Conference/Events
First Mid-Illinois Bancshares management to meet with Stephens »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Jun

  • 24

    Sep

STE

STERIS

$106.73

-0.82 (-0.76%)

13:37
06/19/18
06/19
13:37
06/19/18
13:37
Conference/Events
STERIS management to meet with Stephens »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Jun

SRPT

Sarepta

$143.85

38.37 (36.38%)

13:35
06/19/18
06/19
13:35
06/19/18
13:35
Recommendations
Sarepta analyst commentary  »

Sarepta price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Jun

HAIN

Hain Celestial

$29.55

0.69 (2.39%)

13:35
06/19/18
06/19
13:35
06/19/18
13:35
Options
Hain Celestial put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

T

AT&T

$32.38

0.175 (0.54%)

, VZ

Verizon

$48.54

1.08 (2.28%)

13:34
06/19/18
06/19
13:34
06/19/18
13:34
Periodicals
AT&T to end sale of user location data to third-party brokers, Verge reports »

AT&T (T) plans to end…

T

AT&T

$32.38

0.175 (0.54%)

VZ

Verizon

$48.54

1.08 (2.28%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Jun

ORCL

Oracle

$46.18

-0.36 (-0.77%)

, MSFT

Microsoft

$100.35

-0.53 (-0.53%)

13:23
06/19/18
06/19
13:23
06/19/18
13:23
Earnings
On The Fly: What to watch for in Oracle's earnings report »

Oracle (ORCL) is…

ORCL

Oracle

$46.18

-0.36 (-0.77%)

MSFT

Microsoft

$100.35

-0.53 (-0.53%)

IBM

IBM

$143.49

-0.96 (-0.66%)

HPE

HP Enterprise

$15.78

-0.14 (-0.88%)

AMZN

Amazon.com

$1,712.48

-11.58 (-0.67%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Jun

  • 10

    Jul

XLU

Utilities SPDR

$49.96

0.27 (0.54%)

13:20
06/19/18
06/19
13:20
06/19/18
13:20
Options
SPDR Repeat put buying in SPDR Utility ETF as the sector sees relative strength »

SPDR Repeat put buying in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

13:20
06/19/18
06/19
13:20
06/19/18
13:20
General news
Treasury Action: so far there's no sign of a general boycott on Treasuries »

Treasury Action: so far…

SNAP

Snap

$12.95

-1.1 (-7.83%)

13:18
06/19/18
06/19
13:18
06/19/18
13:18
Periodicals
Snap adds to original programming with docu-series, Variety says »

According to Variety,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

13:17
06/19/18
06/19
13:17
06/19/18
13:17
Technical Analysis
NASDAQ market internals summary »

Volume is above average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

$0.00

(0.00%)

13:16
06/19/18
06/19
13:16
06/19/18
13:16
Technical Analysis
NYSE market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

I

Intelsat

$16.06

-0.46 (-2.78%)

13:15
06/19/18
06/19
13:15
06/19/18
13:15
Options
Intelsat put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.